September 22, 2022
The phase 3 PRESTO trial had 3 arms: ADT alone; ADT plus apalutamide; and ADT plus apalutamide plus abiraterone/prednisone.
September 18, 2022
“These data do suggest that [enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda)] is a viable treatment option for cisplatin-ineligible patients,” says Jonathan E. Rosenberg, MD.
September 15, 2022
“There were no serious skin events that occurred on this study, which I think is a credit to the study team that worked with the investigators to manage the manage the toxicity and prevent serious skin reactions,” says Jonathan E. Rosenberg, MD.
"When the blood tests were positive, workups were typically completed in less than 3 months. I think this is really a new concept. It shows it is feasible to detect cancers using blood tests," said Deb Schrag, MD, MPH.
September 14, 2022
“Responses occurred across all International mRCC Database Consortium risk groups—both in the favorable and intermediate/poor risk groups,” said Jamie R. Merchan, MD.
September 13, 2022
The patient had previously received 6 lines of chemotherapy treatment and was still in an ongoing complete response at the time of the study analysis.
Data showed that nivolumab followed by nivolumab/ipilimumab resulted in an overall response rate of 34%.
September 12, 2022
The results of the study are particularly encouraging given the high unmet need for patients with non–clear cell renal cell carcinoma, according to lead investigator Laurence Albiges, MD, PhD.
The findings are from the EV-103 trial and were presented at the 2022 ESMO Congress by lead investigator Jonathan E. Rosenberg, MD.
“The study was stopped for futility after the second prespecified interim analysis based on guidance from the external data monitoring committee,” said Evan Y. Yu, MD.
